NO20044095L - 5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer - Google Patents

5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer

Info

Publication number: NO20044095L
Authority: NO; Norway
Prior art keywords: kinase inhibitors; phenylthiazole derivatives; phenylthiazole; derivatives; kinase
Prior art date: 2002-02-28

Application number

NO20044095A

Other languages

English (en)

Other versions

NO329175B1 (no

Inventor

Judy Hayler

Clive Mccarthy

Lan Bruce

Peter Finan

Catherine Leblanc

Lewis Whitehead

Nicola Elaine Press

Graham Charles Bloomfield

Louise Kirman

Mrinalini Sachin Oza

Lena Shukla

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-28

Filing date

2004-09-27

Publication date

2004-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044095(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-02-28 Priority claimed from GB0204765A external-priority patent/GB0204765D0/en

2002-12-19 Priority claimed from GB0229626A external-priority patent/GB0229626D0/en

2004-09-27 Application filed by Novartis Ag filed Critical Novartis Ag

2004-11-02 Publication of NO20044095L publication Critical patent/NO20044095L/no

2010-09-06 Publication of NO329175B1 publication Critical patent/NO329175B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Virology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Endocrinology (AREA)

NO20044095A 2002-02-28 2004-09-27 5-fenyltiazolderivater, fremgangsmate for fremstilling derav, anvendelse av en slik forbindelse samt farmasoytisk sammensetning inneholdende forbindelsen NO329175B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0204765A GB0204765D0 (en)	2002-02-28	2002-02-28	Organic compounds
GB0229626A GB0229626D0 (en)	2002-12-19	2002-12-19	Organic compounds
PCT/EP2003/002036 WO2003072557A1 (en)	2002-02-28	2003-02-27	5-phenylthiazole derivatives and use as pi3 kinase inhibitors

Publications (2)

Publication Number	Publication Date
NO20044095L true NO20044095L (no)	2004-11-02
NO329175B1 NO329175B1 (no)	2010-09-06

Family

ID=27767104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044095A NO329175B1 (no)	2002-02-28	2004-09-27	5-fenyltiazolderivater, fremgangsmate for fremstilling derav, anvendelse av en slik forbindelse samt farmasoytisk sammensetning inneholdende forbindelsen

Country Status (27)

Country	Link
US (2)	US7687637B2 (no)
EP (1)	EP1480962B1 (no)
JP (2)	JP4408701B2 (no)
KR (1)	KR100688370B1 (no)
CN (1)	CN100548996C (no)
AR (1)	AR038703A1 (no)
AT (1)	ATE521598T1 (no)
AU (1)	AU2003214080A1 (no)
BR (1)	BR0308030A (no)
CA (1)	CA2477601C (no)
CO (1)	CO5611131A2 (no)
CY (2)	CY1112084T1 (no)
DK (2)	DK2311818T3 (no)
EC (2)	ECSP045253A (no)
ES (2)	ES2405816T3 (no)
IL (2)	IL163691A0 (no)
MX (1)	MXPA04008362A (no)
MY (1)	MY156407A (no)
NO (1)	NO329175B1 (no)
NZ (1)	NZ534657A (no)
PE (1)	PE20030968A1 (no)
PL (2)	PL219449B1 (no)
PT (2)	PT1480962E (no)
RU (2)	RU2378263C2 (no)
SI (1)	SI1480962T1 (no)
TW (1)	TWI314928B (no)
WO (1)	WO2003072557A1 (no)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003523166A (ja)	1998-09-29	2003-08-05	ガミダセルリミテッド	幹細胞および前駆細胞の増殖と分化を制御する方法
IL152904A0 (en)	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en)	2002-01-25	2006-06-07	Gamida Cell Ltd	PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
EP1603905A1 (en)	2003-02-10	2005-12-14	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
GB0305152D0 (en) *	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
WO2004087138A1 (en) *	2003-03-31	2004-10-14	Sucampo Ag	Method for treating vascular hyperpermeable disease
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en)	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
RS50521B (sr) *	2004-01-12	2010-05-07	Applied Research Systems Ars Holding N.V.	Derivati tiazola i njihova upotreba
KR101280095B1 (ko)	2004-08-28	2013-09-09	아스트라제네카 아베	케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체
RU2403258C2 (ru)	2004-10-07	2010-11-10	Бёрингер Ингельхайм Интернациональ Гмбх	Тиазолилдигидроиндазолы
UY29149A1 (es) *	2004-10-07	2006-05-31	Boehringer Ingelheim Int	Tiazolil-dihidro-indazoles
SE0402735D0 (sv)	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
WO2006117567A2 (en) *	2005-05-05	2006-11-09	Chroma Therapeutics Ltd	Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
UA96735C2 (en) *	2005-05-24	2011-12-12	Мерк Сероно Са	Thiazole derivatives and use thereof
EP1885716B1 (en)	2005-05-24	2012-11-07	Merck Serono SA	Thiazole derivatives and use thereof
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
CA2631750A1 (en)	2005-12-01	2007-06-07	The Scripps Research Institute	Compositions and methods for inducing neuronal differentiation
GB0525671D0 (en) *	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
KR20080091369A (ko) *	2006-01-18	2008-10-10	암젠 인크	단백질 키나제 ｂ（ｐｋｂ） 억제제로서 티아졸 화합물
WO2007098826A2 (en) *	2006-01-18	2007-09-07	Siena Biotech S.P.A.	Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
JP2009523769A (ja) *	2006-01-23	2009-06-25	ラボラトワールセローノソシエテアノニム	チアゾール誘導体及びこれらの使用
US20070238746A1 (en) *	2006-04-06	2007-10-11	Trixi Brandl	Thiazolyl-dihydro-chinazoline
US7691868B2 (en)	2006-04-06	2010-04-06	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-quinazoline
US7517995B2 (en) *	2006-04-06	2009-04-14	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-cyclopentapyrazole
US20090076009A1 (en) *	2006-05-03	2009-03-19	Arnould Jean-Claude Retired	Thiazole derivatives and their use as anti-tumour agents
GB0608854D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	P13 kinase inhibitors
GB0608823D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	Inhibitors of P13 kinase
GB0610243D0 (en) *	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
RU2435763C2 (ru) *	2006-06-27	2011-12-10	Дзе Проктер Энд Гэмбл Компани	Ингибиторы тирозинфосфатазы белка человека и способы применения
US7589212B2 (en) *	2006-06-27	2009-09-15	Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
DE602006003651D1 (de) *	2006-08-03	2008-12-24	Cellzome Ag	Verfahren zur Identifizierung von Molekülen die mit PI3K interagieren und Verfahren zur Reinigung von PI3K
WO2008027584A2 (en) *	2006-09-01	2008-03-06	Vertex Pharmaceuticals Incorporated	5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
CA2670736A1 (en) *	2006-11-29	2008-06-05	Abbott Laboratories	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
PE20090717A1 (es) *	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
US8158677B2 (en)	2007-06-01	2012-04-17	The Trustees Of Princeton University	Treatment of viral infections by modulation of host cell metabolic pathways
JP2010533715A (ja)	2007-07-17	2010-10-28	アムジエン・インコーポレーテツド	複素環系ｐｋｂ調節剤
CA2693473A1 (en) *	2007-07-17	2009-01-22	Amgen Inc.	Thiadiazole modulators of pkb
UY31545A1 (es)	2007-12-20	2009-08-03		Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
DK2245181T3 (da)	2008-02-04	2012-02-06	Cellzome Ag	Selektivitetsprofilering af PI3K-interagerende molekyler med multiple mål
UA104147C2 (uk)	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101684106B (zh) *	2008-09-22	2013-06-12	北京摩力克科技有限公司	噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
PL2404908T3 (pl) *	2009-02-27	2014-12-31	Teijin Ltd	Sposób wytwarzania podstawionej fenylem pochodnej heterocyklicznej przez sprzężenie z użyciem katalizatora metalu przejściowego
WO2010125799A1 (ja) *	2009-04-27	2010-11-04	塩野義製薬株式会社	Pi3k阻害活性を有するウレア誘導体
UY32748A (es)	2009-07-02	2011-01-31	Novartis Ag	2-carboxamida-cicloamino-ureas
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
GB0913345D0 (en)	2009-07-31	2009-09-16	Astrazeneca Ab	New combination 802
EP2492269A4 (en)	2009-10-19	2013-08-07	Taisho Pharmaceutical Co Ltd	aminothiazole
WO2011061527A1 (en)	2009-11-17	2011-05-26	Astrazeneca Ab	Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
KR101942212B1 (ko)	2010-02-03	2019-01-24	시그날 파마소티칼 엘엘씨	Ｔｏｒ 키나제 억제자에 대한 민감성 예측 바이오마커로서 ｌｋｂ1 돌연변이의 동정
GB2485886A (en) *	2010-11-24	2012-05-30	Lithera Inc	Injectable formulations comprising a lipophilic glucocorticosteroid for regional adiposity reduction
GB201021979D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	New compound
GB201021992D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	Compound
WO2013019927A1 (en)	2011-08-03	2013-02-07	Signal Pharmaceuticals, Llc	Identification of gene expression profile as a predictive biomarker for lkb1 status
US9309236B2 (en)	2011-10-05	2016-04-12	The Board Of Trustees Of The Leland Stanford Junior University	PI-kinase inhibitors with broad spectrum anti-infective activity
US9926309B2 (en)	2011-10-05	2018-03-27	The Board Of Trustees Of The Leland Stanford Junior University	Pi-kinase inhibitors with anti-infective activity
EP2814951B1 (en)	2012-02-13	2019-04-03	Gamida-Cell Ltd.	Culturing of mesenchymal stem cells
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
KR102240356B1 (ko)	2013-04-17	2021-04-14	시그날 파마소티칼 엘엘씨	Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
HK1221144A1 (zh)	2013-04-17	2017-05-26	西格诺药品有限公司	用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
SG11201508302PA (en)	2013-04-17	2015-11-27	Signal Pharm Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
US9359364B2 (en)	2013-04-17	2016-06-07	Signal Pharmaceuticals, Llc	Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
EP2986298A1 (en)	2013-04-17	2016-02-24	Signal Pharmaceuticals, LLC	Treatment of cancer with dihydropyrazino-pyrazines
SG10201801965RA (en)	2013-04-17	2018-04-27	Signal Pharm Llc	Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CN105407892B (zh)	2013-05-29	2019-05-07	西格诺药品有限公司	一种化合物的药物组合物、其固体形式及它们的使用方法
CN104418858B (zh)	2013-08-30	2018-12-11	浙江医药股份有限公司新昌制药厂	2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
DE102013226711A1 (de) *	2013-12-19	2015-06-25	Beiersdorf Ag	Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (en)	2014-04-16	2017-09-20	Signal Pharmaceuticals, LLC	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015162584A1 (en)	2014-04-24	2015-10-29	Novartis Ag	Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
WO2016065583A1 (en)	2014-10-30	2016-05-06	Merck Sharp & Dohme Corp.	Oxazole orexin receptor antagonists
EP3344599B1 (en) *	2015-09-04	2020-12-09	Dow Agrosciences LLC	Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
EP3344600B1 (en) *	2015-09-04	2021-02-24	Dow Agrosciences LLC	Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
CA2997393A1 (en) *	2015-09-10	2017-03-16	Dow Agrosciences Llc	Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
EP3395801B1 (en) *	2015-12-16	2021-03-31	Nippon Soda Co., Ltd.	Arylazole compound and pest control agent
US10808017B2 (en)	2016-02-01	2020-10-20	The Governing Council Of The University Of Toronto	Ubiquitin variants and uses therof as 53BP1 inhibitors
WO2017147526A1 (en) *	2016-02-26	2017-08-31	The Board Of Trustees Of The Leland Stanford Junior University	Pi-kinase inhibitors with anti-infective activity
SG11201912403SA (en)	2017-06-22	2020-01-30	Celgene Corp	Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
US12000833B2 (en)	2017-11-23	2024-06-04	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Marker for predicting the sensitivity to PI3K inhibitors
CA3134417A1 (en)	2019-03-21	2020-09-24	The Board Of Trustees Of The Leland Stanford Junior University	Pi4-kinase inhibitors and methods of using the same
WO2021038426A1 (en) *	2019-08-28	2021-03-04	Novartis Ag	Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
CN115028596B (zh) *	2021-03-03	2024-06-07	帕潘纳(北京)科技有限公司	制备苯唑草酮中间体的方法
KR20250153183A (ko)	2022-12-19	2025-10-24	카마우 테라퓨틱스, 인크.	P53 결합 단백질인 53bp1의 개선된 펩타이드 저해제

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB951885A (en)	1961-05-13	1964-03-11	Sankyo Co	A new process for the preparation of thiazole compounds
OA01933A (fr)	1965-04-06	1970-02-04	Pechiney Saint Gobain	Dérivés du thiazole.
US3749775A (en) *	1969-07-07	1973-07-31	Stauffer Chemical Co	Insecticidal 2-aminothiazole phosphates and phosphonates
FR2429210A1 (fr)	1978-06-19	1980-01-18	Fabre Sa Pierre	Derives de phenyl-4 thiazolyl-2 oxamates utiles dans le traitement de l'asthme
JPS57136579A (en)	1981-01-21	1982-08-23	Mitsui Toatsu Chem Inc	Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
US4511574A (en)	1981-01-08	1985-04-16	Mitsui Toatsu Kagaku Kabushiki Kaisha	N-(4-Phenyl-2-thiazolyl)carbamate derivatives
DE3413755A1 (de)	1984-04-12	1985-10-24	Basf Ag, 6700 Ludwigshafen	Thiazolylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPH0725754B2 (ja)	1986-01-30	1995-03-22	富山化学工業株式会社	新規なチアゾール化合物またはその塩
DE3864248D1 (de)	1987-12-14	1991-09-19	Sawai Seiyaku Kk	Carboxamide mit tetrazol- und thiazol-ringen und ihre anwendung.
US4891375A (en)	1988-01-13	1990-01-02	Pfizer Inc.	Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
DE69132944T2 (de)	1990-11-30	2002-11-21	Otsuka Pharmaceutical Co., Ltd.	Azolederivate als Inhibitor von Superoxide-Radikalen
DE4401911A1 (de)	1994-01-24	1995-08-03	Basf Ag	Verwendung von Aryl- oder Heteroarylazoanilinen in der nichtlinearen Optik
CA2195847A1 (en)	1994-07-27	1996-02-08	John J. Talley	Substituted thiazoles for the treatment of inflammation
DE69526958T2 (de) *	1994-11-29	2003-01-16	Hisamitsu Pharmaceutical Co., Inc.	Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten
GB9625843D0 (en) *	1996-12-12	1997-01-29	Merck & Co Inc	Phenyl spiroethercycloalkyl tachykinn receptor antagonists
IL136767A0 (en)	1997-12-22	2001-06-14	Bayer Ag	Inhibition of raf kinase using substituted heterocyclic ureas
EP0928790B1 (en) *	1998-01-02	2003-03-05	F. Hoffmann-La Roche Ag	Thiazole derivatives
US6100282A (en) *	1998-01-02	2000-08-08	Hoffman-La Roche Inc.	Thiazole derivatives
US6043254A (en)	1998-04-03	2000-03-28	Boehringer Ingelheim Pharma Kg	Indolinones having kinase-inhibiting activity
GB9823873D0 (en) *	1998-10-30	1998-12-30	Pharmacia & Upjohn Spa	2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
AU3042601A (en)	2000-01-24	2001-07-31	Thrombogenix Pty Ltd	Therapeutic morpholino-substituted compounds
US6518277B1 (en)	2000-04-25	2003-02-11	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
SI21099A (sl)	2000-07-26	2003-06-30	Bristol-Myers Squibb Company	N-(5-(((5-alkil-2-oksazolil)metil)tio)-2-tiazolil) karboksamidni inhibitorji ciklin odvisnih kinaz
EP1844766B1 (en)	2000-12-18	2012-04-18	Institute of Medicinal Molecular Design, Inc.	Inhibitors against the production and release of inflammatory cytokines
AR039059A1 (es) *	2001-08-06	2005-02-09	Sanofi Aventis	Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
WO2003015717A2 (en) *	2001-08-17	2003-02-27	Merck & Co., Inc.	Tyrosine kinase inhibitors
US6812653B2 (en) *	2002-07-26	2004-11-02	Richard S. Bellivean	Method and apparatus for controlling images with image projection lighting devices
GB0525671D0 (en) *	2005-12-16	2006-01-25	Novartis Ag	Organic compounds

2003
- 2003-02-26 TW TW092104036A patent/TWI314928B/zh not_active IP Right Cessation
- 2003-02-26 PE PE2003000188A patent/PE20030968A1/es not_active Application Discontinuation
- 2003-02-26 AR ARP030100626A patent/AR038703A1/es active IP Right Grant
- 2003-02-26 MY MYPI20030662A patent/MY156407A/en unknown
- 2003-02-27 DK DK10174528.9T patent/DK2311818T3/da active
- 2003-02-27 PL PL403456A patent/PL219449B1/pl unknown
- 2003-02-27 RU RU2004129279/04A patent/RU2378263C2/ru not_active IP Right Cessation
- 2003-02-27 EP EP03709730A patent/EP1480962B1/en not_active Expired - Lifetime
- 2003-02-27 CN CNB038047969A patent/CN100548996C/zh not_active Expired - Fee Related
- 2003-02-27 BR BR0308030-7A patent/BR0308030A/pt not_active IP Right Cessation
- 2003-02-27 PT PT03709730T patent/PT1480962E/pt unknown
- 2003-02-27 ES ES10174528T patent/ES2405816T3/es not_active Expired - Lifetime
- 2003-02-27 PL PL370575A patent/PL215581B1/pl unknown
- 2003-02-27 AT AT03709730T patent/ATE521598T1/de active
- 2003-02-27 CA CA2477601A patent/CA2477601C/en not_active Expired - Fee Related
- 2003-02-27 WO PCT/EP2003/002036 patent/WO2003072557A1/en not_active Ceased
- 2003-02-27 KR KR1020047013419A patent/KR100688370B1/ko not_active Expired - Fee Related
- 2003-02-27 SI SI200332074T patent/SI1480962T1/sl unknown
- 2003-02-27 DK DK03709730.0T patent/DK1480962T3/da active
- 2003-02-27 RU RU2009132712/04A patent/RU2436780C2/ru not_active IP Right Cessation
- 2003-02-27 ES ES03709730T patent/ES2372597T3/es not_active Expired - Lifetime
- 2003-02-27 NZ NZ534657A patent/NZ534657A/en not_active IP Right Cessation
- 2003-02-27 IL IL16369103A patent/IL163691A0/xx unknown
- 2003-02-27 AU AU2003214080A patent/AU2003214080A1/en not_active Abandoned
- 2003-02-27 MX MXPA04008362A patent/MXPA04008362A/es active IP Right Grant
- 2003-02-27 PT PT101745289T patent/PT2311818E/pt unknown
- 2003-02-27 US US10/504,259 patent/US7687637B2/en not_active Expired - Fee Related
- 2003-02-27 JP JP2003571263A patent/JP4408701B2/ja not_active Expired - Fee Related
2004
- 2004-08-23 IL IL163691A patent/IL163691A/en not_active IP Right Cessation
- 2004-08-28 EC EC2004005253A patent/ECSP045253A/es unknown
- 2004-09-15 CO CO04091790A patent/CO5611131A2/es active IP Right Grant
- 2004-09-27 NO NO20044095A patent/NO329175B1/no not_active IP Right Cessation
2009
- 2009-08-12 JP JP2009187248A patent/JP2009298799A/ja active Pending
- 2009-12-17 US US12/640,479 patent/US8129541B2/en not_active Expired - Fee Related
2010
- 2010-08-30 EC EC2010005253A patent/ECSP105253A/es unknown
2011
- 2011-11-24 CY CY20111101144T patent/CY1112084T1/el unknown
2013
- 2013-04-16 CY CY20131100312T patent/CY1114083T1/el unknown

Also Published As

Publication number	Publication date
ECSP045253A (es)	2004-09-28
CY1112084T1 (el)	2015-11-04
MXPA04008362A (es)	2004-11-26
TW200303750A (en)	2003-09-16
ECSP105253A (es)	2010-09-30
US20100093690A1 (en)	2010-04-15
NZ534657A (en)	2007-05-31
AR038703A1 (es)	2005-01-26
CN1639139A (zh)	2005-07-13
WO2003072557A1 (en)	2003-09-04
PL219449B1 (pl)	2015-04-30
KR20040091674A (ko)	2004-10-28
DK1480962T3 (da)	2011-12-05
EP1480962A1 (en)	2004-12-01
HK1071363A1 (en)	2005-07-15
PL215581B1 (pl)	2013-12-31
PL403456A1 (pl)	2013-05-27
DK2311818T3 (da)	2013-05-06
RU2004129279A (ru)	2005-06-27
PT1480962E (pt)	2011-12-15
BR0308030A (pt)	2004-12-28
US7687637B2 (en)	2010-03-30
AU2003214080A1 (en)	2003-09-09
RU2378263C2 (ru)	2010-01-10
RU2009132712A (ru)	2011-03-10
ES2372597T3 (es)	2012-01-24
JP4408701B2 (ja)	2010-02-03
US20050119320A1 (en)	2005-06-02
JP2005522458A (ja)	2005-07-28
CY1114083T1 (el)	2016-07-27
KR100688370B1 (ko)	2007-03-02
US8129541B2 (en)	2012-03-06
PE20030968A1 (es)	2004-01-12
RU2436780C2 (ru)	2011-12-20
CN100548996C (zh)	2009-10-14
MY156407A (en)	2016-02-26
NO329175B1 (no)	2010-09-06
EP1480962B1 (en)	2011-08-24
PT2311818E (pt)	2013-05-15
ATE521598T1 (de)	2011-09-15
PL370575A1 (en)	2005-05-30
CO5611131A2 (es)	2006-02-28
IL163691A (en)	2010-11-30
SI1480962T1 (sl)	2011-12-30
TWI314928B (en)	2009-09-21
JP2009298799A (ja)	2009-12-24
CA2477601A1 (en)	2003-09-04
IL163691A0 (en)	2005-12-18
CA2477601C (en)	2011-05-24
ES2405816T3 (es)	2013-06-03

Publication	Publication Date	Title
NO20044095L (no)	2004-11-02	5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer
NO20053356L (no)	2005-07-11	Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK1648426T3 (da)	2014-02-10	Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
DK1499311T3 (da)	2010-03-08	Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1527050T3 (da)	2010-07-19	Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
DK1480955T3 (da)	2007-10-29	O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DK1501815T3 (da)	2007-04-02	Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
DK1558615T3 (da)	2007-12-03	Purin-forbindelser og deres anvendelse som cannabinoid receptor ligander
NO20026010D0 (no)	2002-12-13	Substituerte quinazolinderivater og deres anvendelse som inhibitorer
DK1465615T3 (da)	2012-11-12	Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
IS7792A (is)	2005-04-11	Hýdantóínafleiður og notkun þeirra sem TACE hemla
DK1492785T3 (da)	2009-03-02	2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1578755T3 (da)	2007-11-12	Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
DK1592686T3 (da)	2009-10-19	Gyrase-inhibitorer og anvendelser deraf
ATE505471T1 (de)	2011-04-15	Azaindol-kinaseinhibitoren
DK1401806T3 (da)	2006-11-27	Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler
NO20052524D0 (no)	2005-05-26	Aminerte isofiavonoidderivater og anvendelse derav
NO20034324D0 (no)	2003-09-26	Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
NO20042719L (no)	2004-06-28	Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20050665L (no)	2005-04-18	Pyrrolidonderivater som MAOE inhibitoere
NO20043580D0 (no)	2004-08-27	Quinazolinonderivater og deres bruk som CB agonister
NO20044665L (no)	2004-12-03	Renzoksazin-derivater som 5-HT6-modulatorer og anvendelser derav
DK1387838T3 (da)	2006-08-14	Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DK1359458T3 (da)	2006-03-20	Brillestel og hængselsenhed til anvendelse deri

Legal Events

Date	Code	Title	Description
2016-09-26	MM1K	Lapsed by not paying the annual fees